Skip to main content
PTN $5.55 -9.39%
PTN logo
PTN · Palatin Technologies Inc
Track PTN — free
$5.55 -0.58 (-9.39%) Earnings today
Market Cap
$10.91M
Shares
1.78M
Volume · Nov 17 37.15K Avg daily vol (3M) 70.26K
All webcasts

Earnings call · FY2027 Q1

Palatin Technologies Inc (PTN) Q1 2027 Earnings Call Transcript

Concluded Nov 17, 2026 Audio replay
Nov 17, 2026 32:39 39 turns
Period
FY2027 Q1
Runtime
32:39
Sources
3 artifacts
Revenue $361,802 -95.9% YoY
Diluted EPS -$1.29 -130.3% YoY
Net income -$5.06M -208.1% YoY
Open full screen 10-Q

Transcript & audio

32:39 Audio
Operator

Welcome to Palatine's First Quarter Fiscal Year 2027 Operating Results Conference Call. As a reminder, this conference call is being recorded. Before we begin our remarks, I would like to remind you that statements made by Palatine are not historical facts and may be forward-looking statements. These statements are based on assumptions that may or may not prove accurate and that actual results may differ materially from those anticipated due to the variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission. Please consider such risks and uncertainties carefully in evaluating these forward-looking statements by Palatine's prospects. Now, I would like to turn the call over to your host, Dr. Carl Spana, President and Chief Executive Officer of Palatine. Please go ahead.

Good morning, and welcome to Paladin's Fiscal First Quarter 2027 call. I am Dr. Carl Spana, CEO and President of Paladin. With me on the call today is Steve Wills, Paladin's Chief Financial Officer and Chief Operating Officer. Steve will lead off the call with the financial and corporate update. Steve.

Thank you, Carl, and good morning, everyone. I'll review our financial results for the fiscal 2027 first quarter ended September 30, 2026. And discuss our operating priorities and provide some perspective on our financial strategy as we move toward important clinical development milestones. During the quarter, we continued to focus our resources on advancing our next-generation MC4R programs, particularly the IND-enabling activities for our lead lipidated peptide and the development of our oral small molecule candidates. We believe these investments are positioning Palatin for an important period of clinical development beginning in calendar year 2027. Regarding fiscal first quarter financial results, for the three months ended September 30, 2026, Palatin recognized approximately $362,000 in collaboration and license revenue, compared with approximately $8.8 million for the comparable prior year period. Current quarter revenue was attributable to research and development services performed under our collaboration with Bernal Engelheim. The prior year period included substantial upfront milestone payments associated with that agreement, which accounts for the year-over-year difference. Turning to expenses, research and development were approximately $3.4 million, compared with approximately $2.5 million in the comparable prior year period. Importantly, spending directly related to our MC4R obesity development programs increased to approximately $2.1 million compared with approximately $1 million in the prior year period. This increase reflects our continued advancement of IND-enabling studies and related development activities for our long-actin peptide program, as well as lead candidate optimization activities for our oral small molecule program. We believe these expenditures represent important investments in advancing our development candidates toward clinical evaluation. General and administrative expenses were approximately $2.1 million, compared with approximately $1.7 million in the comparable prior year period. The increase was primarily attributable to a higher stock-based compensation expense and professional fees. For the fiscal first quarter, we reported a net loss of approximately $5.1 million, or $1.29 per basic and diluted common share. Regarding Peloton's cash position and financial strategy, net cash used in operating activities was approximately $3.7 million during the quarter, compared with approximately $1.6 million in the prior year period. As of September 30th, 2026, we had approximately $3.7 million in cash and cash equivalents. We recognize that advancing our development programs through the next stages of clinical development will require additional capital. We are evaluating financing alternatives, including public and private equity transactions, while continuing to pursue strategic collaborations and other opportunities to support our programs. Our financing strategy is directed toward obtaining the capital necessary to execute our development plans and achieve the milestones that we believe can create substantial value for Paliton and its shareholders. We have successfully accessed the capital markets and executed strategic transactions throughout Paliton's history, and we remain focused on pursuing the financial resources required to advance our programs. At the same time, we continue to carefully manage operating expenditures and prioritize investment in our highest value development opportunities. Regarding strategic partnerships and operating priorities, an important component of our strategy is utilizing our broader Milano Corton portfolio to create additional opportunities for value through licensing and collaboration agreements. Our partnership with Brengel Engelheim and our licensing arrangement with Altona SPAC Labs We also continue to evaluate strategic opportunities for our other development assets in the MC1R landscape. Looking ahead, our operating priorities remain clear. First, advance our lead lipidated MC4R peptide candidate through the necessary IND-enabling and manufacturing activities toward initiation of a Phase I clinical study in the first half of calendar year 2027. Second, progress our oral small molecule MC4R program toward candidate selection, IND-enabling development, and planned clinical initiation in the second half of calendar year 2027. Third, Continue expanding the opportunities within our MC4R portfolio, including our non-lipidated peptide series and oral peptide approach. And fourth, secure the financial and strategic resources necessary to support these objectives. In closing, Palatin is entering an important period in its development. Our strategic direction is clearly established. Our next-generation MC4R programs are advancing, and our research and development investments are increasingly concentrated on programs with the potential for significant clinical and commercial differentiation. We believe Palatin has the scientific expertise, proprietary compounds, and development capabilities to compete effectively in this emerging market. We remain confident in the potential of our programs. And committed to advancing them through the next important stages of development. With that, I'll turn the call back to Carl. Carl?

Thank you, Steve. Today, I want to focus on the significant opportunity we see for Palatin with our next generation of melanocortin-4 receptor-targeted therapies, the progress we are making across our development programs and the important milestones ahead. The treatment landscape for rare neuroendocrine obesity disorders continues to evolve rapidly. Importantly, the melanocortin 4 receptor, or MCR4 receptor agonism, has now been clinically and commercially validated as a therapeutic approach for patients with certain rare obesity disorders driven by dysfunctions in the melanocortin pathway. This validation is important. It establishes that activating the MCR4 receptor can deliver meaningful clinical benefits in diseases that have historically been extremely difficult to treat. This provides substantial opportunities for novel, differentiated MCR-4 therapeutics, which is where Palatin is focused. Our objective is to develop next-generation MCR-4 agonists with the potential to deliver robust efficacy, substantially improved tolerability, minimal or no hyperpigmentation, and dosing profiles that are practical with patients who may require treatment throughout their lives. We are applying our extensive knowledge of melanocortin receptor pharmacology, peptide engineering, and drug development to create therapies designed to address the limitations of existing and emerging products. An important differentiating characteristic of our development programs is receptor selectivity. The melanocortin-4 receptor is the receptor principally associated with the regulation of appetite, food intake, and energy balance, while the melanocortin-1 receptor is involved in skin pigmentation. Activation of the melanocortin-1 receptor can cause skin darkening or hyperpigmentation, which has emerged as a challenge in the development of MCR-4-based agonist therapeutics. For patients with rare obesity disorders who may require lifelong treatment, minimizing these or this effect is important. Our strategy is to selectively activate the melanocortin-4 receptor while avoiding MCR-1 activity. Tested compounds from our two next-generation peptide series have demonstrated potent melanocortin-4 receptor agonist activity without acting as agonists at the melanocortin-1 receptor. We believe this is a meaningful achievement and supports our objective of substantially reducing and potentially eliminating all MCR1-mediated hyperpigmentation. Our goal is to develop MCR-4 therapeutics with clinically meaningful efficacy without requiring patients to accept unnecessary adverse effects associated with off-target receptor activation. We believe this is going to be an important differentiating factor. Turning to our LEAD program, we continue to make progress advancing our lipid-dated, long-acting monoclonal receptor-selective peptide towards clinical development. Our LEAD candidate is part of our FL2000 peptide series. In preclinical studies using diet-induced obese mice, this candidate demonstrated significant reductions in food intake and body weight following once-weekly subcutaneous administration. Importantly, pharmacokinetic findings in larger animals support the potential for once-weekly or even less frequent dosing in units. These attributes are central to our development strategy. For patients with chronic lifelong conditions such as hypothalamic obesity, Crater-Willi syndrome, and Bardet-Vidal syndrome, a therapy that combines robust efficacy with convenient dosing and improved tolerability could represent or does represent important advancements in the field. Our libidated peptide approach is designed to extend drug exposure and pharmacological activity, potentially enabling sustained therapeutic benefits with fewer injections. We are currently advancing the IND, enabling preclinical and manufacturing activities necessary to support our first in-human study. We are targeting initiatives of a Phase I single, multiple, and multiple ascending dose study in the first half of calendar 2027, with initial clinical data target to occur in the second half of the year. This represents an important upcoming milestone for Palatin. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics of our next-generation lipidated peptide in humans, and also include measurements of skin pigmentation, body weight, body mass index, and effects on appetite. We believe the combination of monocotin-4 receptor selectivity, sustained activity, and demonstrated preclinical efficacy makes this an especially promising development candidate. We also continue to advance our non-lipidated TL-1000 peptide series, including formulation strategies intended to support long-acting administration. Together, these programs provide multiple opportunities to develop differentiated peptide-based melanocortin-4 receptor therapies. Beyond our injectable peptide programs, we see significant opportunity in oral melanocortin-4 receptor therapies. Oral administration has obvious appeal for patients and caregivers managing chronic conditions. We believe our extensive medicinal chemistry and pharmacology experience provides a strong foundation for addressing the challenges associated with earlier linoquantin 4-receptor oil programs. Our next-generation oil small molecule program builds on the knowledge gained from our prior development candidate, PL7737, and our broader linoquantin 4-receptor discovery efforts. We have now identified compounds with improved potency and MCR-4 selectivity compared with earlier candidates, together with favorable worldwide availability and preclinical evaluations. We continue to optimize these candidates with a particular emphasis on potency, receptor selectivity, gastrointestinal tolerability, and suitability for chronic administration. Our target is to advance a selected candidate into IND-enabling development in the first half of 2027 and to initiate a Phase I clinical study in the second half of calendar 2027. Additionally, our oral peptide agonist approach has made significant progress. We have developed selective melanocortin 4-receptor agonists with gastrointestinal stability and oral bioavailability that supports further development. Although this effort is earlier in development, it provides a compelling opportunity to develop novel, orally-delivered MCR4 peptide therapeutics and expands the range of technologies and therapeutic profiles that we can pursue. Our goal is to develop a portfolio best-in-class melanocotin-4-receptive therapies, rather than depending on a single molecule or delivery approach. There is growing interest in novel monocortin-4-receptor-based therapeutics, and Palatin is very well positioned to take advantage of this interest and deliver best-in-class therapeutics. First, we have extensive experience with the melanocortin-receptor system, including the development of remelanotide, the first monocortin-4-receptor compound approved by the FDA. Second, we have generated a substantial body of proprietary medicinal chemistry, pharmacology, and clinical development knowledge that informs the design of our next-generation compounds. Third, our development strategies focus on specific clinical limitations that have become apparent with existing and emerging therapies. And fourth, we are pursuing multiple complementary approaches, including lipidated injectable peptides, non-lipidated peptide formulations, oral small molecules, and oral peptide approaches. We believe these capabilities position us to develop highly differentiated therapies in a market where therapeutic mechanism has been well-validated and where meaningful, unmet medical need remains. In addition to our internal melanocortin 4-receptive development programs, we continue to realize value from our Florida melanocortin portfolio. Our collaboration with Bungle Ingelheim for retinal diseases provides ongoing research reimbursement and the potential for additional development, regulatory, and commercial milestone payments and royalties. Our agreement with Altanaspac Labs transfers future development responsibility for PL9643 and dry eye disease while preserving potential future economics for palatins. We also continue to evaluate partnering opportunities for our additional clinical stage and proof-of-concept programs. These arrangements reflect an important element of our overall strategy, maintaining our proprietary focus on melanocortin-4 receptor obesity development while utilizing collaborations and licensing mechanisms to advance other assets. Before turning the call over to questions, I want to emphasize one final point. We believe the melanocortin-4 receptor system represents one of the most compelling validated mechanisms for treating rare neuroendocrine obesity disorders. The opportunity now is to build better medicines around this mechanism. Our next-generation programs are specifically designed to do that. We have demonstrated compelling preclinical characteristics, including potent monoclonal receptor agonism without monoclonal receptor activation, intestinal compounds, and sustained activity with our lead libidata peptide. We are advancing these programs toward human clinical evaluation with important milestones targeted throughout 2027. With that, I will turn the call over to questions.

Operator

Thank you. The floor is now open for questions. If you wish to join the queue to ask a question at this time, please press star 1. We do ask if listening on speakerphone today, please pick up your handset while asking your question to provide optimal sound quality. Once again, please press star 1 on your phone at this time to join the queue to ask a question. First question from Scott Henry with AGP. Please go ahead.

Scott Henry Analyst — AGP

Thank you, and good morning. I'll start with sort of the big picture. We've seen a lot of interest around the MC4R pathway in peptides. Certainly reports of interest in Rhythm Pharmaceuticals from AstraZeneca. We've got Gilead and Pepstar. What does this activity... Suggest to you about the pathway. I mean, it certainly seems like interest is heating up. And how do you believe Palatine is positioned within this environment?

Thanks, Scott. I think it's self-evident, right? It shows you that there's a growing interest in this mechanism on both the peptide front and the small molecule front. We're seeing a lot more interest coming inbounds. A lot more companies are approaching us. So we're quite excited about where the mechanism sits. You know, with a growing interest, you know,

outside of not just, you know, specialty pharma, but large pharma as evidenced by AstraZeneca.

In general, overall, you know, peptides are becoming a lot more interesting in the sense that, you know, the ability to lipidate peptides, to increase, you know, to reduce the number of injections, so going from either one or more injections per day to one injection per week or even longer, and the fact that many of these lipidated peptides can be stabilized for oral delivery. Really is opening up the field. So large pharma is yet again revisiting peptides as a validated therapeutic approach. And this is all based off of the success that's been seen with the GLP-1s. So overall, I think there's a very big positive for the melanocortin field and the peptides in general, the interest that AstraZeneca and others are showing in the target.

And I think from a palate perspective, we're very well positioned.

We were a peptide company. We've developed lots of peptide agonists and antagonists. We have lots of core technologies for, you know, understanding how to lipidate these peptides correctly so that they maintain selectivity and reduce the number of injections and good potency. And now, you know, we've been able to essentially open up the aspect of giving oral delivery with these peptides as well. We were able to generate both lipidated and non-lipidated peptides that are extremely stable in gastrointestinal fluid and intestinal fluid as well.

And they're showing oral bioavailability in the range that allows them to be one way of the oral delivery.

So we feel we're really well positioned across the board.

Scott Henry Analyst — AGP

Okay, thank you for that color. And, you know, a natural extension to that question, as investors look at Rhythm as sort of a comp for Paliton, how would you compare and contrast what you're doing versus what Rhythm is working on?

Listen, I mean, Rhythm has been very successful in pioneering the use of MCR for agonists for treating rare and orphan indications. So, I mean, and so that it really opened up the field. And as I said on the call, it's now about, you know, getting the best compounds. It's really developing better, you know, either peptide or small molecule drugs to come into that marketplace that provide, you know, better attributes and differentiate attributes for patients. You know, we believe on a peptide front that lipidated approach is superior to using polymers. Polymer approaches do work, but they have their limitations, whereas lipidated peptides don't. You can draw the direct analogy for what was done with the GLP-1s. You know, they started out as, you know, once or twice a day injectables, they went to polymers, and then they went to lipidation, and lipidated drugs really have taken off. They're just easier to use. The better the formula, they're easier to use. You can titrate, and you have a lot more flexibility. So we believe a little bit of peptide that reduces MCR1 activity. And maintains high MCR4 potency

is really going to be a superior product to the peptide approaches that are out there.

On the small molecule front, the goal here is there's one out there. It's okay. It's a first generation. I think that the type of compounds that we're working on and others may be working on are going to be superior with regards to selectivity, potency, and overall drug-like characteristics that are going to allow them just to be dosed in an easier format and a wider dosing range to potentially drive more efficacy. So I think, of course, the board, we're very differentiated from what Rhythm has done. But with that being said, you know, they're out there. They're the first, and they're pioneering these markets. And, you know, our intent is to come along with superior and differentiated products and be competitive. And I feel that we're there with the compounds that we're bringing forward.

Scott Henry Analyst — AGP

Okay, great. Thank you for that color. Perhaps I'll give Steve a chance to speak. Steve, given the heightened interest around the sector, does that make you feel much more confident? I know financing is an important need. It doesn't look like the warrants are going to come into play just quite yet. So do you think this background enhances the outlook for financing in the near term? Thank you.

The – absolutely. First of all, thanks for the question, Scott, there. The – you know, we absolutely have to recognize the importance of securing additional capital to support the next stages of our development programs, and that's really the – you know, notwithstanding the advancement of the MCR for obesity program, that's our key corporate priority. We've operated more than 25 years. We're 100% successful regarding accessing the capital markets, also executing strategic transactions, and that's been done through multiple development cycles and market landscapes. As Carl highlighted, we have a compelling portfolio of next-generation MC4R programs that we believe are... Differentiated from, albeit, the commercial programs out there and the programs under development. We, of course, are actively evaluating financing alternatives, public-private equity, and we're looking at strategic opportunities there. The interest is significantly greater over the last several months than it's ever been at Palatine, and the MCR4 landscape is the primary factor in that regard. But since Nostradamus has not returned my calls, we cannot provide assurances regarding the timing. Or the terms of a transaction, but we're focused on advancing the programs and pursuing the resources necessary to achieve our objectives.

Scott Henry Analyst — AGP

Okay, great. Thank you. Just a couple minor questions for you, Carl, just follow-ups. First, So on the peptide front, you're working on PL-1000, which is the non-lipidated, and PL-2000, the lipidated. My understanding is that PL-2000, the lipidated, is in the lead between those two compounds, and it appears you're going to take that one into the clinic first. Is that correct?

That's correct. That's correct. Again, we have both what we call simple peptides, which are essentially, these are, you know, cyclized peptides that are very true. They look like remelanotide. They would look like setmelanotide. These would be, you know, daily injectable type of product. And they'd have to be formulated in polymers or other types of technologies if you wanted extended delivery. So we're going forward with lipidated. Lipidated, we think, is a superior product and a superior approach to long-term delivery of peptides.

Scott Henry Analyst — AGP

Okay, and the other question I just had was, the oral small molecule compound, it seems like that timeline sort of shifted up a little bit with data now expected in the first half of 28. Is that correct? Or perhaps I was just being conservative expecting it in second half of 28. And thank you for taking all of these questions.

I'll jump in on timelines there, Scott and Steve. No, we haven't changed that. The oral small molecule program and also the oral peptide program is tracking approximately two quarters behind the lipidated peptide program. So with the first half target for the lipid A peptide, starting the phase one. Phase 1 and data by the end of the second half of 2027. Just reverse that for the oral small molecule and or the oral peptide. It should be starting in the second half of 2027 with data in the first half of calendar 2028.

Scott Henry Analyst — AGP

Okay, great. Thank you for taking the question.

Operator

Thank you. Next question is from Joe Pantjenis with H.C. Wainwright. Please go ahead.

Josh Analyst — H.C. Wainwright

Hi, this is Josh. I'm for Joe. Thanks for taking our questions. So, I had a few questions on the Obesity Week data. So you had some nice selectivity for MCR4 over MC1R. So I'm just curious your thoughts on this in relation to hyperpigmentation and kind of your confidence on how this is going to translate into patients.

Sure. One question. The goal is to eliminate, or as much as possible, MCR1 activity so that you can avoid hyperpigmentation. So in treating these conditions that we're talking about, these are chronic conditions. They're lifelong treatments. And so having the best profile is one that allows patients to stay on the longest. And hyperpigmentation can be a side effect of having MCR1 activity that a number of patients don't necessarily want to experience. So, being able to have the high degree of selectivity that we have, and again, when we talk about selectivity in a couple of different ways, and I don't want to get too technical, but the most important way we think about it is really reducing the activity of your compounds against the receptor, and that's a little bit different than what other people are doing. So we're pretty confident that we've achieved that. And as we go into the clinic, we do expect to see diminished or no pigmentation. But again, until we get to the clinic, you're not going to know. The animal models for predicting hyperpigmentation are... They're not that well-validated. So we do them, we run them, but I think overall, you know, you've got to go on your selectivity and your activity profile and get in the clinic.

Josh Analyst — H.C. Wainwright

Okay. And you also had some early blood pressure effects. So I'm just curious what additional work that you're thinking of doing to further establish this cardiovascular profile.

So, I mean, the cardiovascular profile is obviously, it's cardiovascular safety for any drug, including melanocorn-4 agonist, is important. There are some legacy issues around potential cardiovascular effects with MCR-4s that we don't have in our compounds. So, we'll continue to evaluate their effects on blood pressure and on rhythm throughout the tox program. So, you know, you'll do that in specific studies that will look at blood pressure and EG retracings as well as in your overall, you know, seven-day, 28-day talks and longer-term talk studies. So, there's nothing unique here. You know, it's the same type of stuff that you would do for all. Any drug going through development. We'll make sure that when we go into the clinic that we have the appropriate methodologies for evaluating blood pressure so that when we come out of the SAD-MAD studies, we expect to have a clean profile.

Josh Analyst — H.C. Wainwright

All right, great. Thanks for taking your questions. I'm definitely excited to see the first in human studies get going. Thanks.

So are we.

Operator

Thank you. Next question from Dev Prasad with Lucid. Please go ahead.

Dev Prasad Analyst — Lucid

Hi, thank you for taking our question. Quick one on the progress of toward the phase one. Can you help? What are the remaining steps from now to initiating the phase one of lead lipidated peptide?

Sure. You know, a lot of the – so if you think about the toxicology program in vitro, so non-animal studies and animal studies, the majority of the in vitro studies have been completed, and we're getting ready to start the 28-day study in both rat and dogs, and that's really the game item. When that's done, you know, in those reports we're in, we'll be able to file. In conjunction with that, we have, of course, the ongoing, you know, CMC requirements for, you know, stability and so on and so forth and making sure that we have both the required documentation around the API or the drug itself as well as the drug product. And those are all on track to be in place, you know, to file in the second quarter of next year.

Dev Prasad Analyst — Lucid

Great. And can you talk about R&D expenses moving forward? Because we see you have a quite substantial expense on the September quarter.

That's over to Steve. Sure, I'll take this one. So the increase in R&D spending, that's obviously directly related to the advancement of our priority development programs. And particularly the IND-enabling activities of our lead-lipidated peptide and the continued optimization of our small molecule and oral peptide candidates. We view this as an important investment in advancing our programs toward the clinical development. As we move closer to initiating the Phase I studies next year, certain development expenses will naturally increase, particularly those associated with... Manufacturing, toxicology, regulatory activities, and the clinical trial preparation. At the same time, we do maintain considerable flexibility in managing the timing and pace of the expenditures. Capital allocation strategy is... Focused on the programs we believe offer the greatest potential, which obviously is our MC4R PC programs, and that means prioritizing the lead long-acting peptide and the old MC4R programs while leveraging partnerships to advance the other assets. And we do believe this disciplined approach allows us to concentrate our resources on the opportunities with the greatest potential to create shareholder value. Great. Thank you for taking the introduction.

Operator

Thank you. Next question from Yael Jun with Lidlaw. Please go ahead.

Yael Jun Analyst — Lidlaw

Good morning, and thanks for taking the question. Carl, you're talking about the lipidated peptide potentially can be used orally. Could you elaborate a little bit more on that, and as well as was there any examples of drug already developed from the lipidated peptide to Oral...

Sure. I mean, the most largest one, obviously, is semaglutide, which was originally developed, obviously, as Ozempic.

Analyst Q&A · 4 questions
Full-screen source Call document